The FDA Oncology Center of Excellence announced a pilot program to help physicians get access to unapproved therapies for patients with cancer.
Project ECHO, a service that provides physicians in rural areas with access to multidisciplinary expertise, will soon announce partnerships with four cancer centers—Dana-Farber Cancer Institute, Mayo Clinic Cancer Center, University of New Mexico Comprehensive Cancer Center, and Yale Cancer Center.
Over the past decade there has been much consternation about overdiagnosis, the detection of cancers that would not have been diagnosed without screening.
Overdiagnosis is defined as the diagnosis of an asymptomatic cancer that would not have become clinically evident during the person's lifetime in the absence of screening or similar activities, such as diagnostic imaging tests that reveal “incidentalomas.”
Community oncology needs to adapt to the era of precision oncology and Big Data, said Lee Schwartzberg, executive director of Memphis-based West Cancer Center, who was recently named chief medical officer of OneOncology, a partnership between three oncology practices located in Tennessee and New York.
Many have written and spoken about the goal of eliminating the effect of developing and delivering medical care in “silos.”
The Tomosynthesis Mammographic Imaging Screening Trial, a massive randomized trial of early detection, is asking an important question:
The number of cases of HPV+ cervical precancers has dropped by 21 percent from 2008 to 2014, according to a survey by the Centers for Disease Control and Prevention.
A University of California, Irvine patient with glioblastoma recently received an experimental cancer vaccine from the U.S. subsidiary of Brussels-based Epitopoietic Research Corp. (ERC-USA). While most cases of patients receiving experimental medical treatment are not particularly newsworthy, this one was.
Last week, the American Cancer Society released its annual Facts and Figures report, showing that we continue to make exceptional progress against cancer, most notably with a 27 percent decline in the death rate across all cancer types over the last 25 years.
